glp-1 compounding news november 2025 New project announcement: HHS‑OIG is taking a closer look at FDA's oversight of compounded GLP‑1 drugs. Although shortages ended in 2025, some facilities may still be producing these drugs at scale. Our FDA and Novo Nordisk Warned

How Troy Watson Monitors Early Progress and Adjusts Semaglutide GLP-1 Treatment for Optimal Results Does Semaglutide GLP-1 work right away for weight loss

In MM patients, 24% of tumors exhibit copy number loss of CDKN2A ( CDK4 , CCND1 , and MDM2 are amplified in 28%, 18%, and 19% of samples respectively, and TP53 mutations occur in 9.0% of MMs ( CDKN2A loss than MM, MM tends to show a greater frequency of CCND1 and CDK4 amplification (120, 122), implying CDK4 blocking agents may achieve a desired anti-tumor effect on MM

How does it work, and what does the science say

Age-Related Decline In the body, GHK-Cu naturally occurs at concentrations of approximately 200 ng/mL in plasma at age 20, but these levels decline progressively with age to less than 80 ng/mL by age 60 - this age-related decline correlates with decreased tissue repair capacity, skin aging, and impaired regenerative responses, leading to the hypothesis that GHK-Cu decline contributes to aging phenotypes and that restoration of youthful levels through supplementation could have anti-aging benefits